Da Volterra Presents New Data Supporting DAV132 As A Promising Candidate To Protect The Intestinal Flora And Prevent Severe Clostridium difficile Infections
5/12/2014 9:28:13 AM
PARIS, France--(BUSINESS WIRE)--Da Volterra, a leading biopharmaceutical company in the field of bacterial resistance, announces today very promising new results about DAV132 in the prevention of the side effects of antibiotics and the occurrence of severe Clostridium difficile infections. The Company presents two posters at ECCMID 2014 (the European Conference of Microbiology and Infectious Diseases) taking place in Barcelona on May 10-13, 2014.
Help employers find you! Check out all the jobs and post your resume.
comments powered by